Mizuho Initiates Coverage of Intrexon with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities today initiated coverage of synthetic biology firm Intrexon with a Buy rating and a price target on the company's shares of $30.

Germantown, Md.-based Intrexon went public in August, raising $184 million in gross proceeds. Mizuho was co-manager on the IPO with Griffin Securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.